Quantifying tumour-infiltrating lymphocyte subsets : a practical immuno-histochemical method

Background: Efficient histological quantification of tumour-infiltrating T and B lymphocyte (TIL) subsets in archival tissues would greatly facilitate investigations of the role of TIL in human cancer biology. We sought to develop such a method. Methods: Ten ×40 digital images of 4 μ sections of 16 ductal invasive breast carcinomas immunostained for CD3, CD4, CD8, and CD20 were acquired (a total of 640 images). The number of pixels in each image matching a partition of Lab colour space corresponding to immunostained cells were counted using the ‘Color range’ and ‘Histogram’ tools in Adobe Photoshop 7. These pixel counts were converted to cell counts per mm2 using a calibration factor derived from one, two, three or all 10 images of each case/antibody combination. Results: Variations in the number of labelled pixels per immunostained cell made individual calibration for each case/antibody combination necessary. Calibration based on two fields containing the most labelled pixels gave a cell count minimally higher (+ 5.3%) than the count based on 10-field calibration, with 95% confidence limits − 14.7 to + 25.3%. As TIL density could vary up to 100-fold between cases, this accuracy and precision are acceptable. Conclusion: The methodology described offers sufficient accuracy, precision and efficiency to quantify the density of TIL sub-populations in breast cancer using commonly available software, and could be adapted to batch processing of image files

Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression

Immune-mediated effector molecules can limit cancer growth, but lack of sustained immune activation in the tumour microenvironment restricts antitumour immunity. New therapeutic approaches that induce a strong and prolonged immune activation would represent a major immunotherapeutic advance. Here we show that the arenaviruses lymphocytic choriomeningitis virus (LCMV) and the clinically used Junin virus vaccine (Candid#1) preferentially replicate in tumour cells in a variety of murine and human cancer models. Viral replication leads to prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control. Mechanistically, LCMV induces antitumour immunity, which depends on the recruitment of interferon-producing Ly6C+ monocytes and additionally enhances tumour-specific CD8+ T cells. In comparison with other clinically evaluated oncolytic viruses and to PD-1 blockade, LCMV treatment shows promising antitumoural benefits. In conclusion, therapeutically administered arenavirus replicates in cancer cells and induces tumour regression by enhancing local immune responses

Testing the theory of immune selection in cancers that break the rules of transplantation

Modification of cancer cells likely to reduce their immunogenicity, including loss or down-regulation of MHC molecules, is now well documented and has become the main support for the concept of immune surveillance. The evidence that these modifications, in fact, result from selection by the immune system is less clear, since the possibility that they may result from reorganized metabolism associated with proliferation or from cell de-differentiation remains. Here, we (a) survey old and new transplantation experiments that test the possibility of selection and (b) survey how transmissible tumours of dogs and Tasmanian devils provide naturally evolved tests of immune surveillance

Einfluss von UVB-Strahlung auf die Expression von Entzündungsfaktoren im Linsenepithel

Ziel und Hintergrund: Ziel dieser Arbeit ist es, den Einfluss von UVB-Strahlung auf die Expression von Entzündungsfaktoren im Linsenepithel in vivo zu untersuchen. Im Fokus stehen dabei die Entzündungsfaktoren MCP-1 und Substanz P mit ihrem Rezeptor NK1R und ihre Beteiligung an einer UVB-induzierten Entzündungsreaktionen im Rahmen der Katarakt-Entwicklung. Die Katarakt ist die häufigste Erblindungsursache der Welt, und es gibt derzeit keine Präventionsstrategien. Im Fokus der Kataraktforschung auf molekularer Ebene standen bisher vor allem die Oxidation der Linsenproteine durch reaktive Sauerstoffspezies als bedeutendster Pathomechanismus der Proteinaggregation und resultierender Kataraktogenese. Allerdings treten Katarakte auch im Rahmen von Zytokin-assoziierten und systemisch entzündlichen Erkrankungen auf. Methoden: C57Bl/6-Mäuse wurden in vivo einseitig UVB-Strahlung ausgesetzt. Jede Maus erhielt eine fünffache Katarakt-Äquivalenzdosis (1,45 kJ/m2) an UVB-Bestrahlung im 300-nm-Wellenlängenbereich unter Verwendung eines Bio-Spectra-Systems. Die Kontrollgruppe erhielt nur eine Anästhesie, aber keine UVB-Bestrahlung. Die NK1R- und MCP-1-Level in Linsenepithel-Lysaten wurden mittels ELISA-Tests (enzyme-linked immunosorbent assay) für das exponierte und auch für das kontralaterale Auge analysiert. Die Morphologie der UVB-induzierten Linsentrübungen wurde mit einem Leica-Dunkelfeldmikroskop-Kamerasystem 3 und 7 Tage nach der UVB-Bestrahlung untersucht und Computer-gestützt quantifiziert als integrierte optische Dichte durch Bestimmung der Pixelintensität. Ergebnisse: Alle UVB-exponierten Mäuse entwickelten Katarakte im exponierten Auge. Die MCP-1- und NK1R-Level im Linsenepithel stiegen nach der UVB-Exposition während der Latenzzeiten von 3 und 7 Tagen an. Ein signifikanter Unterschied wurde für die NK1R-Level zwischen dem exponierten und dem kontralateralen Auge 3 Tage nach der Exposition gefunden. Schlussfolgerung: UVB-Strahlung induziert 3 und 7 Tage nach Exposition in vivo eine Katarakt. Außerdem fanden wir Hinweise darauf, dass die Kataraktbildung mit einer Entzündungsreaktion im Linsenepithel verbunden ist, die möglicherweise durch NKR-1 vermittelt wird. Zukünftig sollte untersucht werden, ob antiinflammatorische Ansätze oder Ansätze zur Verstärkung der regenerativen Funktion von Zytokinen der Katarakt-Entwicklung entgegenwirken

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy

BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. Although TKIs are effective, drug resistance caused by the emergence of drug-selected secondary mutations in BCR-ABL remains a major problem for relapse, especially in patients with compound mutations. In this study, we aimed to investigate potential neoepitopes derived from mutated BCR-ABL and to generate neoepitope-specific TCRs for adoptive T cell therapy. Two candidate peptides derived from the E255V and the T315I mutation (designated ABL-E255V and ABL-T315I) were selected for study based on their in silico predicted binding affinity to HLA-A2. By immunizing transgenic mice that express a diverse human T cell receptor (TCR) repertoire restricted to HLA-A2, we detected CD8+ T cell responses against the ABL-E255V, but not the ABL-T315I peptide. From immune responding mice, two E255V-specific TCRs were isolated. Human CD8+ T cells were engineered to express the specific TCRs for characterization, in which one TCR was identified as a therapeutic candidate due to its superior avidity and lack of detectable off-target reactivity. Importantly, we demonstrated that the ABL-E255V neoepitope was naturally processed and presented. In summary, our results demonstrate that HLA-A2+ CML cells harboring the E255V mutation can be targeted by specific TCRs, which may benefit patients who are highly resistant to available TKIs due to compound mutations

Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance

T cell surveillance is often effective against virus-associated tumors because of their high immunogenicity. It is not clear why surveillance occasionally fails, particularly against hepatitis B virus- or hepatitis C virus-associated hepatocellular carcinoma (HCC). We established a transgenic murine model of virus-induced HCC by hepatocyte-specific adenovirus-induced activation of the oncogenic SV40 large T antigen (TAg). Adenovirus infection induced cytotoxic T lymphocytes (CTLs) targeted against the virus and TAg, leading to clearance of the infected cells. Despite the presence of functional, antigen-specific T cells, a few virus-infected cells escaped immune clearance and progressed to HCC. These cells expressed TAg at levels similar to HCC isolated from neonatal TAg-tolerant mice, suggesting that CTL clearance does not select for cells with low immunogenicity. Virus-infected mice revealed significantly greater T cell infiltration in early-stage HCC compared with that in late-stage HCC, demonstrating progressive local immune suppression through inefficient T cell infiltration. Programmed cell death protein-1 (PD-1) and its ligand PD-L1 were expressed in all TAg-specific CD8+ T cells and HCC, respectively, which contributed to local tumor-antigen-specific tolerance. Thus, we have developed a model of virus-induced HCC that may allow for a better understanding of human HCC

Expression of tumour-specific antigens underlies cancer immunoediting

Cancer immunoediting is a process by which immune cells, particularly lymphocytes of the adaptive immune system, protect the host from the development of cancer and alter tumour progression by driving the outgrowth of tumour cells with decreased sensitivity to immune attack1, 2. Carcinogen-induced mouse models of cancer have shown that primary tumour susceptibility is thereby enhanced in immune-compromised mice, whereas the capacity for such tumours to grow after transplantation into wild-type mice is reduced2, 3. However, many questions about the process of cancer immunoediting remain unanswered, in part because of the known antigenic complexity and heterogeneity of carcinogen-induced tumours4. Here we adapted a genetically engineered, autochthonous mouse model of sarcomagenesis to investigate the process of cancer immunoediting. This system allows us to monitor the onset and growth of immunogenic and non-immunogenic tumours induced in situ that harbour identical genetic and histopathological characteristics. By comparing the development of such tumours in immune-competent mice with their development in mice with broad immunodeficiency or specific antigenic tolerance, we show that recognition of tumour-specific antigens by lymphocytes is critical for immunoediting against sarcomas. Furthermore, primary sarcomas were edited to become less immunogenic through the selective outgrowth of cells that were able to escape T lymphocyte attack. Loss of tumour antigen expression or presentation on major histocompatibility complex I was necessary and sufficient for this immunoediting process to occur. These results highlight the importance of tumour-specific-antigen expression in immune surveillance, and potentially, immunotherapy.National Institutes of Health (U.S.) (Grant 1 U54 CA126515-01)National Cancer Institute (U.S.) (Cancer Center Support Grant P30-CA14051)Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship AwardJohnD. Proctor FoundationDaniel K. Ludwig Schola

Identification and ranking of recurrent neo-epitopes in cancer

BACKGROUND: Immune escape is one of the hallmarks of cancer and several new treatment approaches attempt to modulate and restore the immune system’s capability to target cancer cells. At the heart of the immune recognition process lies antigen presentation from somatic mutations. These neo-epitopes are emerging as attractive targets for cancer immunotherapy and new strategies for rapid identification of relevant candidates have become a priority. METHOS: We carefully screen TCGA data sets for recurrent somatic amino acid exchanges and apply MHC class I binding predictions. RESULTS: We propose a method for in silico selection and prioritization of candidates which have a high potential for neo-antigen generation and are likely to appear in multiple patients. While the percentage of patients carrying a specific neo-epitope and HLA-type combination is relatively small, the sheer number of new patients leads to surprisingly high reoccurence numbers. We identify 769 epitopes which are expected to occur in 77629 patients per year. CONCLUSION: While our candidate list will definitely contain false positives, the results provide an objective order for wet-lab testing of reusable neo-epitopes. Thus recurrent neo-epitopes may be suitable to supplement existing personalized T cell treatment approaches with precision treatment options

Identification and ranking of recurrent neo-epitopes in cancer

Neo-epitopes are emerging as attractive targets for cancer immunotherapy and new strategies for rapid identification of relevant candidates have become a priority. We propose a method for in silico selection of candidates which have a high potential for neo-antigen generation and are likely to appear in multiple patients. This is achieved by carefully screening 33 TCGA data sets for recurrent somatic amino acid exchanges and, for the 1,055 resulting recurrent variants, applying MHC class I binding prediction algorithms. A preliminary confirmation of epitope binding and recognition by CD8 T cells has been carried out for a couple of candidates in humanized mice. Recurrent neo-epitopes may be suitable to supplement existing personalized T cell treatment approaches with precision treatment options